TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
Saved in:
| Title: | TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer. |
|---|---|
| Authors: | Meijer D; Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Room Be 432, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands., Jansen MP, Look MP, Ruigrok-Ritstier K, van Staveren IL, Sieuwerts AM, van Agthoven T, Foekens JA, Dorssers LC, Berns EM |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2009 Jan; Vol. 113 (2), pp. 253-60. Date of Electronic Publication: 2008 Feb 26. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
